(Albany, United States) As per DelveInsight’s assessment, globally, the Hepatitis-b-Virus Infection pipeline constitutes 80+ key companies continuously working towards developing 80+ Hepatitis-b-Virus Infection treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

In the Hepatitis-b-Virus Infection Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Hepatitis-b-Virus Infection NDA approvals (if any), and product development activities comprising the technology, Hepatitis B Virus (HBV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

To explore more information on the latest breakthroughs in the Hepatitis-b-Virus Infection Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-pipeline-insight

Key Takeaways from the Hepatitis-b-Virus Infection Pipeline Report

• DelveInsight’s Hepatitis-b-Virus Infection Pipeline analysis depicts a robust space with 80+ active players working to develop 80+ pipeline treatment therapies.
• The leading Hepatitis-b-Virus Infection Companies are working in the market include Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Nucorion Pharmaceuticals, Gilead Sciences, Dong-A ST Co., Ltd., Assembly Biosciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals, and others
• Promising Hepatitis-B-Virus Infection Pipeline Therapies in the various stages of development include EYP001a, HB-AS02V, HBVAXPRO vaccine, FENDRIX, Tenofovir Disoproxil Fumarate, NCO-48 Fumarate 4 mg, Telbivudine, valtorcitabine, Selgantolimod, lamivudine, APG-1387 for Injection, and others
• On June 2023, Gilead Sciences has announced drug named Tenofovir Alafenamide, VIR-2218, and Selgantolimod in the market by the phase 2. The primary objectives of this study are to evaluate the safety and tolerability of study treatment(s) (selgantolimod-containing combination therapies) and to evaluate the efficacy of study treatment(s) as measured by the proportion of participants who achieve functional cure, defined as hepatitis B surface antigen (HBsAg) loss and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) < lower limit of quantitation (LLOQ) at Follow-up (FU) Week 24 in participants with chronic hepatitis B (CHB).
• On January 2023, Nucorion Pharmaceuticals Inc has announced NCO-48 Fumarate 4 mg, and Tenofovir Alafenamide 25 mg in the market by the phase 1. This is a randomized, open-label, active comparator, multiple oral dose study to evaluate the safety, tolerability, pharmacokinetics, and anti-hepatitis B virus (HBV) activity of NCO-48 Fumarate in treatment-naive adults with chronic HBV infection. This study will evaluate the safety, viral kinetics, and antiviral activity of 2 different doses of NCO-48 Fumarate over 28 days of therapy. In addition, the study will evaluate the antiviral activity of an optimal dose of NCO-48 Fumarate versus 25 mg tenofovir alafenamide (TAF) over 28 days of therapy.

Hepatitis-b-Virus Infection Overview

Hepatitis B virus is a small DNA virus that belongs to the “Hepadnaviridae” family. It is a vaccine-preventable liver infection caused by the HBV. A hepatitis B infection can result in either an acute infection or a chronic infection.

Chronic hepatitis B infection can be treated with medicines, including oral antiviral agents. The treatment can result in slowing the progression of cirrhosis, reduce incidence of liver cancer and improve long term survival. Peginterferon alfa 2-acan also be used in treatment as it stimulates the immune system to attack the HBV and regain control over it.

For further information, refer to the detailed Hepatitis-b-Virus Infection Unmet Needs, click here for Hepatitis-b-Virus Infection Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/hepatitis-b-virus-hbv-infection-pipeline-insight

Hepatitis-b-Virus Infection Emerging Drugs Profile

• VIR 2218: Vir Biotechnology
• ABI H3733: Assembly Biosciences
• AB 729: Arbutus Biopharma

Hepatitis-B-Virus Infection Pipeline Therapeutics Assessment

There are approx. 80+ Hepatitis-b-Virus Infection companies which are developing the therapies for Hepatitis B Virus (HBV) Infection. The Hepatitis-b-Virus Infection companies which have their Hepatitis B Virus (HBV) Infection drug candidates in the most advanced stage, i.e. phase II include, Arbutus Biopharma.

Request a sample and discover the recent advances in Hepatitis-b-Virus Infection Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/hepatitis-b-virus-hbv-infection-pipeline-insight

Hepatitis-b-Virus Infection Drugs and Companies

• PBGENE-HBV: Precision Biosciences
• SBT8230: Silverback Therapeutics
• VIR-3434: Vir Biotechnology
• RG6346: Dicerna Pharmaceuticals
• RG7854: Roche
• Pradefovir: Ligand Pharmaceutical
• AB 729: Arbutus bio

Hepatitis-B-Virus Infection Market Drivers

• High prevalence of chronic HBV infection
• Rising case of liver cancer and cirrhosis deaths due to HBV infection

Hepatitis-B-Virus Infection Market Barriers

• Expensive Treatment
• Limited access to the diagnosis

Hepatitis B Virus Infection Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Hepatitis B Virus Infection Therapeutics Market include-

Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Nucorion Pharmaceuticals, Gilead Sciences, Dong-A ST Co., Ltd., Assembly Biosciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals, and others.

Dive deep into rich insights for drugs for Hepatitis-b-Virus Infection Pipeline, click here for Hepatitis-b-Virus Infection Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/hepatitis-b-virus-hbv-infection-pipeline-insight

Scope of the Hepatitis-b-Virus Infection Pipeline Report

• Coverage- Global
• Hepatitis-b-Virus Infection Companies- Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Nucorion Pharmaceuticals, Gilead Sciences, Dong-A ST Co., Ltd., Assembly Biosciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals, and others.
• Hepatitis-b-Virus Infection Therapies- EYP001a, HB-AS02V, HBVAXPRO vaccine, FENDRIX, Tenofovir Disoproxil Fumarate, NCO-48 Fumarate 4 mg, Telbivudine, valtorcitabine, Selgantolimod, lamivudine, APG-1387 for Injection, and others
• Hepatitis B Virus Infection Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Hepatitis-b-Virus Infection Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/hepatitis-b-virus-hbv-infection-pipeline-insight

Table of Content

1. Introduction
2. Executive Summary
3. Hepatitis B Virus (HBV) Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hepatitis B Virus (HBV) Infection– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. AB 729: Arbutus Biopharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ABI H3733: Assembly Biosciences
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Hepatitis B Virus (HBV) Infection Key Companies
21. Hepatitis B Virus (HBV) Infection Key Products
22. Hepatitis B Virus (HBV) Infection- Unmet Needs
23. Hepatitis B Virus (HBV) Infection- Market Drivers and Barriers
24. Hepatitis B Virus (HBV) Infection- Future Perspectives and Conclusion
25. Hepatitis B Virus (HBV) Infection Analyst Views
26. Hepatitis B Virus (HBV) Infection Key Companies
27. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/out-licensing-opportunity